Ahmed Alanazi/X
May 9, 2025, 13:01
Ahmed Alanazi: T-DXd Achieves Primary Endpoint in Early Breast Cancer Neoadjuvant Trial (DB-11)
Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:
“BREAKING NEWS| PRESS RELASE
T-DXD at early setting breast cancer as NACT DB-11 TDXD followed by THP VS standard of care ddAC-THP achieved its primary endpoint pCR statistically and clinically meaningful
Rates of interstitial lung disease (ILD) were similar across the T-DXD followed by THP and the ddAC-THP arms
TDXD WINS AGAIN and now in eBC
waiting for 2ndry endpoints EFS in the future to be matured.”
More posts featuring Breast Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 12:49
May 9, 2025, 12:42
May 9, 2025, 12:26
May 9, 2025, 11:53